No Data
Individual stock information.
BTM <5247.T> rebounded significantly after eight days of decline. A 1-for-2 Stock Splits will be carried out with March 31 as the record date and April 1 as the effective date. Palma <3461.T> continued to rise significantly. It will change markets from the Tokyo Growth Market to the Tokyo Standard Market on the 7th. DeltaF <4598.T> rebounded. The Phase 1 portion (dose setting) of the clinical trial for 'DFP-10917' in combination with 'Venetoclax (VEN)' targeting patients with acute myeloid leukemia in the second-line treatment.
Strong, supported by rising US stocks and declining US long-term interest rates.
[Emerging Markets Individual Stock Global Strategy] Today's Emerging Markets are expected to have a steady performance. On the US stock market at the end of last week on February 28, the Dow Inc rose by 601.41 points (+1.39%) to 43,840.91 dollars, showing a significant rebound after three days. The Core PCE price index confirmed the expected trend of slowing inflation, strengthening the buying pressure due to rate cut expectations. On the other hand, the breakdown of the US and Ukraine summit discussions diminished hopes for a ceasefire, putting pressure on stock prices; however, as the end of the month approached, there was a strong tendency for buybacks, leading to an increase in market momentum towards the end.
Palma, BTM and other [Emerging Markets press release]
＜265A＞ Acquisition of a portion of the business from IP Partners, which is engaged in IT consulting, etc. ＜3133＞ Complete subsidiary acquisition of NEPAL HYDRO POWER HOLDINGS, which develops and operates renewable Energy projects overseas through a simple stock exchange ＜3461＞ Approval granted for the market change to the standard market on the Tokyo Stock Exchange ＜3542＞ Completion of the repurchase of VEGA's own shares ＜4450＞ PSOL from the fiscal year ending December 2025 to January 2027.
Delta-Fly Pharma, Inc.: Progress of Development Status of the Combination Study of DFP-10917 With Venetoclax
Delta-Fly Pharma: 3Q financial results presentation materials for the fiscal year ending 2025/3 20250214
Delta-Fly Pharma Sees Parent FY Loss Y1.83B